Physician
Desert Pain Specialists, LLC
Desert Pain Specialists, LLC was paid $1.80M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 58% of everything it billed.
33Billing provider infoDESERT PAIN SPECIALISTS, LLC
SAINT GEORGE, UT 84790
SAINT GEORGE, UT 84790
33aNPI1871762450assigned 02/27/2008
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$1.80M
24GClaims53,279
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Utah
Rank by total paid#2 of 21
Median peer was paid$19K
This provider vs. median94×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,611 | $87K | |
| 2019 | 8,927 | $90K | |
| 2020 | 6,150 | $93K | |
| 2021 | 8,606 | $310K | |
| 2022 | 7,886 | $334K | |
| 2023 | 6,650 | $393K | |
| 2024incomplete | 7,449 | $490K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 58% | 17,107 | 14,901 | $1.04M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 6,463 | 5,863 | $262K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 5.8% | 1,005 | 957 | $105K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 5.4% | 958 | 923 | $96K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 4.7% | 1,030 | 962 | $85K |
| 62323 | 3.0% | 397 | 378 | $53K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2.1% | 95 | 64 | $38K |
| 64483 | 1.5% | 216 | 183 | $27K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1.4% | 5,219 | 4,505 | $26K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.2% | 316 | 306 | $21K |
| 20553 | <1% | 267 | 246 | $10K | |
| 62321 | <1% | 53 | 52 | $7K |
28 more codes
| 99152 | <1% | 618 | $6K | |
| 64615 | <1% | 55 | $4K | |
| 20610 | <1% | 129 | $4K | |
| 77002 | <1% | 182 | $3K | |
| 64484 | <1% | 41 | $2K | |
| 27096 | <1% | 16 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $632.88 |
| 80305 | <1% | 750 | $523.38 | |
| G9577 | Patients prescribed opiates for longer than six weeks | <1% | 199 | $133.83 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | <1% | 204 | $107.20 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | <1% | 4,961 | $56.89 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,435 | $53.88 |
| G2065 | Comprehensive care management for a single high-risk disease services, e.g. principal care management, at least 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities | <1% | 18 | $37.15 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,271 | $2.78 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 7,930 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 365 | $0.00 |
| 4040F | 0% | 589 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 305 | $0.00 |
| G9622 | Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method | 0% | 98 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 89 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 112 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 123 | $0.00 |
| 4004F | 0% | 33 | $0.00 | |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 288 | $0.00 |
| 1036F | 0% | 194 | $0.00 | |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 82 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEMPEY, JOSEPH (PRESIDENT)